Major depressive disorder (MDD) impacts millions globally, with conventional treatments often proving limited in success. This has fueled the exploration of novel therapeutic approaches. Among these, ketamine has emerged as a potential candidate for MDD treatment. Ketamine is a hallucinogenic agent with rapid antidepressant effects, unlike typical